Maxim analyst Jason McCarthy noted that Gedeon Richter and STADA Arzneimittel AG have withdrawn their respective MAAs for biosimilar Neulasta, which he said may put Coherus Biosciences in a good position in terms of the competitive landscape for the drug in Europe. Novartis (NVS) and Mylan (MYL) had filed before Coherus and Apotex may file in 2017, noted McCarthy. In the U.S., Novartis' BLA was rejected by the FDA and Coherus could have a two-year head start in commercialization of biosimilar Neulasta, added the analyst, who has a Buy rating and $43 price target on Coherus shares.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.